Drug intelligence / Profile preview

LY4560736

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LY4560736 is an investigational amyloid-targeting therapeutic candidate being developed by Eli Lilly and Company for the treatment of Alzheimer's disease. It is currently being evaluated in a Phase 1 clinical trial (NCT07843459) under a master protocol (A1D-MC-ATMP) to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and participants with Alzheimer's disease. The drug is administered via intravenous (IV) or subcutaneous (SC) routes and is designed to target and inhibit amyloid-beta protein accumulation in the brain.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on LY4560736.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4560736.